Capricor Therapeutics (CAPR) News Today → If you have $2,500 bucks… check this out (From DTI) (Ad) Free CAPR Stock Alerts $5.41 +0.26 (+5.05%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBuy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancementsmarkets.businessinsider.com - April 27 at 7:27 PMCapricor Therapeutics (NASDAQ:CAPR) Earns Buy Rating from HC Wainwrightamericanbankingnews.com - April 27 at 3:48 AMCapricor aligns with FDA on drug pathway for muscular dystrophyuk.investing.com - April 26 at 1:22 PMOptimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Positionmarkets.businessinsider.com - April 25 at 8:15 PMCapricor Therapeutics' (CAPR) "Buy" Rating Reiterated at HC Wainwrightmarketbeat.com - April 25 at 8:09 AMCapricor Therapeutics (NASDAQ:CAPR) Stock Price Crosses Above Fifty Day Moving Average of $5.56americanbankingnews.com - April 25 at 4:17 AMCapricor Announces Positive Type-B Interaction With FDA For CAP-1002 In Treating DMDmarkets.businessinsider.com - April 24 at 4:52 PMHere's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situationfinance.yahoo.com - April 24 at 4:52 PMCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophyglobenewswire.com - April 24 at 9:00 AMNurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicinemarkets.businessinsider.com - April 19 at 5:39 PMWall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Knowfinance.yahoo.com - April 10 at 2:18 PMCapricor Therapeutics Inc (CAPR)investing.com - April 3 at 6:22 PMCapricor Therapeutics to Present at Upcoming Investor Conferencesglobenewswire.com - March 21 at 8:30 AMBuy Rating Affirmed for Cyclo Therapeutics on Strong Clinical and Financial Prospectsmarkets.businessinsider.com - March 19 at 8:41 PMFY2024 Earnings Estimate for Capricor Therapeutics Inc Issued By Cantor Fitzgerald (NASDAQ:CAPR)marketbeat.com - March 18 at 2:04 AMEarnings Beat: Capricor Therapeutics, Inc. (NASDAQ:CAPR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecastsfinance.yahoo.com - March 14 at 8:59 AMBuy Rating Affirmed: Lineage Therap’s Growth and Innovation Poised to Transform Biotech Landscapemarkets.businessinsider.com - March 12 at 7:01 PMCapricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progressmarkets.businessinsider.com - March 6 at 4:46 PMCapricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conferenceglobenewswire.com - March 6 at 8:30 AMCapricor Therapeutics Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - March 3 at 8:51 AMCapricor Therapeutics, Inc. (CAPR) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 3 at 12:25 AMCapricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 2 at 9:24 AMQ4 2023 Capricor Therapeutics Inc Earnings Callfinance.yahoo.com - March 1 at 9:53 AMHC Wainwright Reaffirms Buy Rating for Capricor Therapeutics (NASDAQ:CAPR)marketbeat.com - March 1 at 8:34 AMRecap: Capricor Therapeutics Q4 Earningsbenzinga.com - February 29 at 7:11 PMCapricor Therapeutics Inc (CAPR) Reports Encouraging Year-End Financials and Advances in DMD Therapyfinance.yahoo.com - February 29 at 7:11 PMCapricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - February 29 at 4:05 PMCapricor Therapeutics's Earnings Outlookbenzinga.com - February 28 at 3:01 PMCapricor Therapeutics is about to announce earnings — here's what Wall Street expectsmarkets.businessinsider.com - February 28 at 3:01 PMAnalysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Rocket Pharmaceuticals (RCKT)markets.businessinsider.com - February 27 at 2:09 PMCapricor Therapeutics Granted Type-B Meeting With FDA For CAP-1002 Muscular Dystrophy Drug, Stock Upmarkets.businessinsider.com - February 27 at 2:09 PMCapricor Therapeutics Shares Rise 8% After FDA Meeting Setmarketwatch.com - February 27 at 2:09 PMCapricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophyglobenewswire.com - February 27 at 8:30 AMCapricor Therapeutics (CAPR) to Release Quarterly Earnings on Thursdaymarketbeat.com - February 23 at 9:50 AMCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29finance.yahoo.com - February 22 at 8:44 AMCapricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29globenewswire.com - February 22 at 8:30 AMCapricor Therapeutics Inc CAPRmorningstar.com - February 20 at 8:19 PMCapricor scales up manufacturing capacity for DMD therapymsn.com - February 20 at 3:18 PMCapricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercializationfinance.yahoo.com - February 20 at 10:18 AMCapricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercializationglobenewswire.com - February 20 at 8:30 AMCAPR Mar 2024 7.500 callfinance.yahoo.com - February 17 at 8:12 AMCAPR Mar 2024 7.500 putfinance.yahoo.com - February 17 at 8:12 AMCapricor Therapeutics (NASDAQ:CAPR) Stock Passes Below 200-Day Moving Average of $4.42marketbeat.com - February 17 at 5:42 AMConstruction consultancy strengthens its hand in Lothian and Fifeuk.news.yahoo.com - February 6 at 9:56 AMFrontier Group Holdings Inc (ULCC) Reports Mixed Q4 and Full Year 2023 Resultsuk.finance.yahoo.com - February 6 at 9:56 AMEurope’s clean industrial strategy demands more strategic investmentmsn.com - February 6 at 9:56 AMCRED to acquire mutual fund startup Kuvera in wealth management pushuk.style.yahoo.com - February 6 at 9:56 AMMarket Sentiment Around Loss-Making Capricor Therapeutics, Inc. (NASDAQ:CAPR)finance.yahoo.com - February 4 at 10:47 AMCapricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50-Day Moving Average of $4.17marketbeat.com - February 1 at 4:19 AMGlobal Exosome Diagnostics and Therapeutics Market 2024-2028 - Rising Demand for Early Cancer Detection Fuels Market Expansionuk.finance.yahoo.com - January 29 at 5:54 PM Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. CAPR Media Mentions By Week CAPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.400.32▲Average Medical News Sentiment CAPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼102▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRVO News Today RGLS News Today IMAB News Today IXHL News Today BPTS News Today AEON News Today PRQR News Today SCPH News Today SYRS News Today GOSS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryWhy Big Pharma is Investing Billions in This BiotechBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
